Latest News

FDA Label Update Positions Inclisiran as First-Line Monotherapy for Hypercholesterolemia /image credit ©muhammed/stock.adobe.com
FDA Label Update Positions Inclisiran as First-Line Monotherapy for Hypercholesterolemia

August 1st 2025

Inclisiran can now be used without a background statin, as an adjunct to changes in diet and physical activity for reduction of LDL-C in hypercholesterolemia.

Tirzepatide Proves Noninferiority with Dulaglutide for MACE in Lilly's Landmark Incretin Face-Off / image credit ©MichaelVI/stock.adobe.com
Tirzepatide Proves Noninferiority with Dulaglutide for MACE in Lilly's Landmark Incretin Face-Off

August 1st 2025

FDA Approves Finerenone for Heart Failure With LVEF ≥40% Following Positive Phase 3 Data
FDA Approves Finerenone for Heart Failure With LVEF ≥40% Following Positive Phase 3 Data

July 14th 2025

GLP-1 Therapy for Obesity Requires Substantial Nutritional Framework, Multidisciplinary Support, Joint Advisory Warns
GLP-1 Therapy for Obesity Requires Substantial Nutritional Framework, Multidisciplinary Support, Joint Advisory Warns

July 9th 2025

BF% outperforms BMI in Predicting Morality risk in young adults: New Findings / image courtesy of University of Florida
Body Fat Percentage Outperforms BMI in Predicting Mortality Risk in Young Adults: New Findings

July 8th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.